Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Endoxifen showed tamoxifen-like, anti-estrogenic effects in breast cancer cells
June 9th, 2005
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) showed anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen (4-OH-Tam). According to a study from the United States, "Tamoxifen is an effective drug for the treatment and prevention of breast cancer. It is extensively metabolized by the human cytochrome p450 enzyme system into several metabolites. Of these, 4-OH-Tam is an active metabolite, which has greater anti-estrogenic potency than the parent drug, tamoxifen." "We reported recently that 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) could also be active. The progesterone receptor (PR) messenger ribonucleic acid (mRNA)...
Source: Women's Health Weekly (2005-06-09)
|
